INNATE PHARMA EUR0.05 (NASDAQ:IPHYF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday. The firm presently has a $13.00 price objective on the stock. Zacks Investment Research’s target price points to a potential upside of 11.21% from the company’s current price.

According to Zacks, “Innate Pharma S.A. is a biopharmaceutical company. It develops drugs for treatment of cancer and inflammatory diseases. The company specializes in the development of first-in-class therapeutic antibodies targeting receptors and pathways controlling the activation of the innate immune system. Innate Pharma S.A. is headquartered in Marseilles, France. “

Separately, Leerink Swann reissued a “buy” rating on shares of INNATE PHARMA EUR0.05 in a research report on Wednesday, August 17th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

INNATE PHARMA EUR0.05 (NASDAQ:IPHYF) traded down 1.68% during mid-day trading on Tuesday, reaching $11.69. The company had a trading volume of 4,750 shares. INNATE PHARMA EUR0.05 has a 12-month low of $10.36 and a 12-month high of $16.08. The stock’s market capitalization is $629.82 million. The stock has a 50 day moving average price of $12.19 and a 200-day moving average price of $12.76.

5 Day Chart for NASDAQ:IPHYF

Get a free copy of the Zacks research report on INNATE PHARMA EUR0.05 (IPHYF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for INNATE PHARMA EUR0.05 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INNATE PHARMA EUR0.05 and related companies with's FREE daily email newsletter.